Transasia-Erba Groups' international hematology range backed by European R&D, now in Ahmedabad

Top Quote Eyes 500 crores in FY2020-21 from hematology in Indian market; Gujarat is home to a significantly large number of thalassemia patients, priced 25% below comparable options, new range to make world-class diagnostics affordable for them. End Quote
  • (1888PressRelease) May 15, 2019 - Transasia-Erba Group, India's No. 1 In-vitro Diagnostic (IVD) Company and among the leading global players focused on emerging markets, today as part of its 40th anniversary celebration announced that its international hematology range, is now available in Ahmedabad. Backed by European R&D, the 3-Part Differential Analyzer (3PDA) to 5-Part Differential Analyzer (5PDA) fully automated haematology analyzers, reagents and controls include a number of features to help institutions, clinicians and lab technologists offer accurate diagnosis. Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in Europe, the H 360, H 560 and ELite 580 hematology analyzers are widely used in the European and global market. Hematology analyzers are extensively used in patient and research settings to count and characterize blood cells for disease detection and monitoring. Basic analyzers return a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. Sophisticated analyzers measure cell morphology and can detect small cell populations to diagnose rare blood conditions.

    In addition to the routine parameters, the new hematology range offers additional parameters such as Platelet Large Cell Ratio (PLCR) and Platelet Large Cell Concentration (PLCC) that are reported by advanced automated hematology analyzers to add more insight to the possible causes of abnormal platelet counts. It has been observed that a majority of these patients suffer from anaemia, thalassemia, sickle cell anaemia, hemophilia and other hemoglobinopathies. The instruments thus become particularly relevant for Gujarat, which after West Bengal, has the highest number of thalassemic patients.

    Addressing the media, Suresh Vazirani, Chairman and Managing Director, Transasia Bio-Medicals Ltd., said, “The Transasia-Erba Group is committed to make India healthy and happy. And to achieve this, we are glad to be introducing our hematology range, here today. Over the years, Ahmedabad has grown to be recognized as a city for medical tourism because of the establishment of a large number of hospitals and medical centres. This obviously has led to a rise in the need for hematology analyzers. Reputed institutes such as BJ Medical College, VS General Hospital, Gujarat Research and Cancer Institute, Institute of Kidney Diseases and Research Centre (IKDRC) and Indian Red Cross Society (IRCS) are undertaking diagnosis of various types of blood disorders. These are apart from many other large government and private institutes. Transasia is participating in various Government aided programs and one of them was started by Hon’ble Prime Minister Narendra Modi while he was the Chief Minister of Gujarat. Transasia’s instruments are installed in various health institutes where more than 1000 samples are analyzed daily.”

    He further added, “At the IRCS particularly, more than 1500 persons are analyzed daily, of children aged over 13 years. That shows the prevalence of various hemoglobinopathies in Gujarat. The Government of Gujarat has a mechanism in place to make Gujarat thalassemia free and Transasia’s instruments are playing a vital role.”

    Highlighting Transasia’s presence in Gujarat, Mrs. Mala Vazirani, Executive Director, said “India ranks 145th among 176 countries on the quality and accessibility of healthcare parameter. Limited access to quality medical infrastructure, including skilled manpower and technologies have been the pain points of over 70% of Indians who live in smaller towns and rural areas. Transasia has a long standing presence of over 25 years in Gujarat. Our reach is not just restricted to Ahmedabad, but we also penetrate the interiors of Rajkot, Godhra, Surat, Mehsana, Baroda and Kutch through our instruments and service team. We have been focusing on indigenous development and technology adoption which facilitates affordable diagnostics through domestic manufacturing.”

    Talking about the newly launched range, Dr. Preet Kaur, M.D. Pathology, Business Unit Head, Transasia said, “Accepted world-over for their quality, precision and ease-of-operation, the Erba range of hematology products will increase the adoption of automated hematology testing among Indian diagnostic labs. The range provides holistic solutions for clinical testing in general and targeted diagnostics which is an added advantage for pediatric and geriatric population. Other unique features include flagging of abnormal samples, RFID, large colored LCD touch screen, customizable reporting formats, ability to connect to a Laboratory Information System (LIS) for result output and ready-to-use reagents that are cyanide free and environment-friendly. By addressing many challenges that labs and pathologists face, Transasia is helping healthcare professionals (HCPs) focus on giving patients the best possible care.”

    About Transasia Bio-Medicals Ltd.:
    Founded in 1979, Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers products and solutions in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics. Transasia provides doctors and patients with reliable, affordable and innovative Medical Diagnostic Systems, with an impressive install base of above 65,000 equipment across India. It has a vast network of the more than 250 service engineers, 400+ sales and marketing team, 23 zonal offices and 350+ distributors. It is the first Indian company to manufacture and export blood analyzers and reagents, in the 1990s. Today, Transasia’s indigenous research has resulted in development of state of the art, ‘Make in India’ products and technologies, enabling its products to be among the best in the world. All along its journey spanning more than four decades, Transasia has been recognized for its commitment to healthcare. It has been conferred ‘The Economic Times Best Brands 2019’ award, ‘India Medical Device - Export Company of the Year’ and the ‘Global Growth Company-2014’ award by the World Economic Forum amongst many others. Headquartered in Mumbai, Transasia is a part of the global Transasia-Erba group. The group has spread its footprint across USA, UK, Germany, Czech Republic, France, Italy, Russia and Turkey through various acquisitions. Transasia-Erba Group’s production sites in India, Czech Republic and USA and R&D centres in France, UK, India and Czech Republic form a hub for indigenous manufacturing of world class deliverables. Today, the group serves millions across 100 countries. For further information, kindly visit
    For editorial queries only contact Sonam of PRHUB @ sonamm ( @ ) prhub dot com/9945017180.

  • FB Icon Twitter Icon In-Icon
Contact Information